Search
forLearn
5 / 801 resultslearn taurine
learn oleanolic acid
learn Karite
learn rosehip
Research
5 / 1000+ results
research IKZF1 and Ikaros Overexpression Results in Alopecia Areata‐Like Phenotype in Mice
Overexpression of IKZF1 and Ikaros causes hair loss in mice similar to alopecia areata.
research 056 IKZF1 and IKAROS overexpression contributes to the pathogenesis of alopecia areata
Too much IKZF1 and Ikaros protein may cause alopecia areata.
research A kindred with mutant IKAROS and autoimmunity
A mutation in the IKZF1 gene causes immune system overactivity, linked to autoimmune diseases like lupus.
research Measurement of Skin Permeation/Penetration of Nanoparticles for Their Safety Evaluation
Nanoparticles don't penetrate intact skin but can enter through pores or damaged skin.
research Pharmaceutical and non-pharmaceutical treatments for migraine: a systematic review of efficacy and safety
Both new medications and non-drug treatments can effectively manage migraines with fewer side effects.
Community Join
5 / 1000+ resultscommunity Kintor long term safety phase 3
Kintor's phase III trial for pyri (KX-826) showed promising safety and efficacy results, with no drug-related sexual dysfunction reported. Users discussed their experiences with pyri, Minoxidil, Dutasteride, and concerns about the validity of the study results.
community Koshine comes under two names apparently
The conversation is about receiving a shipment of Koshine, also known as Kintor, which is an anti-androgen treatment for hair loss. The user is eager to try the KX-826 product and observe its effects and any side effects.
community Kintors interim report from 9-2-24 for everyone whos interested
Kintor plans to release pyrilutamide foam and a plant-based Koshine by year-end, with GT20029 progressing in their pipeline. Users are pleased about the absence of propylene glycol (PG) in the new products.
community Kintor Pharma Announces Completion of First Patient Enrollment in KX-826 Long-term Safety Phase III Trial for Treatment of AGA
Kintor Pharma has finished enrolling the first patient in a Phase III trial for KX-826, a treatment for androgenetic alopecia (AGA). One user has set a reminder to check back on the topic in a year.
community Kintor to launch pyrilutamide as a cosmetic
Kintor is launching pyrilutamide as a cosmetic for hair loss. Users discuss its potential, comparing it to Cosmerna.